Search Results - "Desai, Ami"

The Evolution of Risk Classification for Neuroblastoma by Sokol, Elizabeth, Desai, Ami V

“…Neuroblastoma is a tumor with great clinical heterogeneity. Patients in North America are risk-stratified using a number of features including age at…”
Get full text

Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project by Sokol, Elizabeth, Desai, Ami V, Applebaum, Mark A, Valteau-Couanet, Dominique, Park, Julie R, Pearson, Andrew D J, Schleiermacher, Gudrun, Irwin, Meredith S, Hogarty, Michael, Naranjo, Arlene, Volchenboum, Samuel, Cohn, Susan L, London, Wendy B

“…The Children's Oncology Group (COG) stratifies the treatment of patients with neuroblastoma on the basis of a combination of biomarkers that include age and…”
Get full text

Poverty and Targeted Immunotherapy: Survival in Children’s Oncology Group Clinical Trials for High-Risk Neuroblastoma by Bona, Kira, Li, Yimei, Winestone, Lena E, Getz, Kelly D, Huang, Yuan-Shung, Fisher, Brian T, Desai, Ami V, Richardson, Troy, Hall, Matt, Naranjo, Arlene, Henderson, Tara O, Aplenc, Richard, Bagatell, Rochelle

“…Abstract Background Whether social determinants of health are associated with survival in the context of pediatric oncology–targeted immunotherapy trials is…”
Get full text

A severe case of delayed transfusion reaction in a patient with sickle cell disease while preparing for allogeneic stem cell transplant by Amit, Michelle, Barsotti, Kellie, Carll, Timothy, Desai, Ami V., Kaviany, Saara

Get full text

Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group by Desai, Ami V, Gilman, Andrew L, Ozkaynak, Mehmet Fevzi, Naranjo, Arlene, London, Wendy B, Tenney, Sheena C, Diccianni, Mitchell, Hank, Jacquelyn A, Parisi, Marguerite T, Shulkin, Barry L, Smith, Malcolm, Moscow, Jeffrey A, Shimada, Hiroyuki, Matthay, Katherine K, Cohn, Susan L, Maris, John M, Bagatell, Rochelle, Sondel, Paul M, Park, Julie R, Yu, Alice L

“…Postconsolidation immunotherapy including dinutuximab, granulocyte-macrophage colony-stimulating factor, and interleukin-2 improved outcomes for patients with…”
Get full text

Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors by Foster, Corey C, Fleming, Gini F, Karrison, Theodore G, Liao, Chih-Yi, Desai, Ami V, Moroney, John W, Ratain, Mark J, Nanda, Rita, Polite, Blase N, Hahn, Olwen M, O'Donnell, Peter H, Vokes, Everett E, Kindler, Hedy L, Hseu, Robyn, Janisch, Linda A, Dai, Julia, Hoffman, Mark D, Weichselbaum, Ralph R, Pitroda, Sean P, Chmura, Steven J, Luke, Jason J

“…CD137 agonism and CSF1R blockade augment stereotactic body radiotherapy (SBRT) and anti-programmed death-1 in preclinical models. We evaluated the safety and…”
Get full text

Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor by Lerman, Benjamin J, Li, Yimei, Carlowicz, Cecilia, Granger, Meaghan, Cash, Thomas, Sadanand, Arhanti, Somers, Katherine, Ranavaya, Aeesha, Weiss, Brian D, Choe, Michelle, Foster, Jennifer H, Pinto, Navin, Morgenstern, Daniel A, Rafael, Margarida Simão, Streby, Keri A, Zeno, Rachel N, Mody, Rajen, Yazdani, Sahr, Desai, Ami V, Macy, Margaret E, Shusterman, Suzanne, Federico, Sara M, Bagatell, Rochelle

“…Although chemoimmunotherapy is widely used for treatment of children with relapsed high-risk neuroblastoma (HRNB), little is known about timing, duration, and…”
Get full text

Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease by Desai, Ami V., Applebaum, Mark A., Karrison, Theodore G., Oppong, Akosua, Yuan, Cindy, Berg, Katherine R., MacQuarrie, Kyle, Sokol, Elizabeth, Hall, Anurekha G., Pinto, Navin, Wolfe, Ian, Mody, Rajen, Shusterman, Suzanne, Smith, Valeria, Foster, Jennifer H., Nassin, Michele, LaBelle, James L., Bagatell, Rochelle, Cohn, Susan L.

“…BACKGROUND High‐risk neuroblastoma patients with end‐induction residual disease commonly receive post‐induction therapy in an effort to increase survival by…”
Get full text

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG) by Desai, Ami V, Robinson, Giles W, Gauvain, Karen, Basu, Ellen M, Macy, Margaret E, Maese, Luke, Whipple, Nicholas S, Sabnis, Amit J, Foster, Jennifer H, Shusterman, Suzanne, Yoon, Janet, Weiss, Brian D, Abdelbaki, Mohamed S, Armstrong, Amy E, Cash, Thomas, Pratilas, Christine A, Corradini, Nadège, Marshall, Lynley V, Farid-Kapadia, Mufiza, Chohan, Saibah, Devlin, Clare, Meneses-Lorente, Georgina, Cardenas, Alison, Hutchinson, Katherine E, Bergthold, Guillaume, Caron, Hubert, Chow Maneval, Edna, Gajjar, Amar, Fox, Elizabeth

“…Abstract Background Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK…”
Get full text

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results by Goldsmith, Kelly C., Park, Julie R., Kayser, Kimberly, Malvar, Jemily, Chi, Yueh-Yun, Groshen, Susan G., Villablanca, Judith G., Krytska, Kateryna, Lai, Lillian M., Acharya, Patricia T., Goodarzian, Fariba, Pawel, Bruce, Shimada, Hiroyuki, Ghazarian, Susan, States, Lisa, Marshall, Lynley, Chesler, Louis, Granger, Meaghan, Desai, Ami V., Mody, Rajen, Morgenstern, Daniel A., Shusterman, Suzanne, Macy, Margaret E., Pinto, Navin, Schleiermacher, Gudrun, Vo, Kieuhoa, Thurm, Holger C., Chen, Joseph, Liyanage, Marlon, Peltz, Gerson, Matthay, Katherine K., Berko, Esther R., Maris, John M., Marachelian, Araz, Mossé, Yael P.

“…Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically to the third-generation ALK inhibitor lorlatinib. We…”
Get full text

Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma by Bao, Riyue, Spranger, Stefani, Hernandez, Kyle, Zha, Yuanyuan, Pytel, Peter, Luke, Jason J, Gajewski, Thomas F, Volchenboum, Samuel L, Cohn, Susan L, Desai, Ami V

“…BackgroundTumor-infiltrating CD8+ T cells and neoantigens are predictors of a favorable prognosis and response to immunotherapy with checkpoint inhibitors in…”
Get full text

Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion by Murray, Elizabeth R., Menezes, Shinelle, Henry, Jack C., Williams, Josie L., Alba-Castellón, Lorena, Baskaran, Priththivika, Quétier, Ivan, Desai, Ami, Marshall, Jacqueline J.T., Rosewell, Ian, Tatari, Marianthi, Rajeeve, Vinothini, Khan, Faraz, Wang, Jun, Kotantaki, Panoraia, Tyler, Eleanor J., Singh, Namrata, Reader, Claire S., Carter, Edward P., Hodivala-Dilke, Kairbaan, Grose, Richard P., Kocher, Hemant M., Gavara, Nuria, Pearce, Oliver, Cutillas, Pedro, Marshall, John F., Cameron, Angus J.M.

“…In pancreatic ductal adenocarcinoma (PDAC), differentiation of pancreatic stellate cells (PSCs) into myofibroblast-like cancer-associated fibroblasts (CAFs)…”
Get full text

Multimodality treatment for recurrent neuroblastoma in the central nervous system by Desai, Ami V., Elmuti, Lena, Cahaney, Christine, De Guzman, Raymond M., Streby, Keri A., Cohn, Susan L.

“…Survival for patients with recurrent central nervous system (CNS) neuroblastoma remains poor. A single‐institutional study demonstrated the potential of…”
Get full text

Healthcare utilization disparities among children with high‐risk neuroblastoma treated on Children's Oncology Group clinical trials by Shoag, Jamie, Li, Yimei, Getz, Kelly D., Huang, Yuan‐Shung, Hall, Matt, Naranjo, Arlene, Richardson, Troy, Desai, Ami V., Umaretiya, Puja J., Aziz‐Bose, Rahela, Kelly, Colleen A., Zheng, Daniel J., Newman, Haley, Zahler, Stacey, Aplenc, Richard, Bagatell, Rochelle, Bona, Kira

“…Introduction Disparities in relapse and survival from high‐risk neuroblastoma (HRNBL) persist among children from historically marginalized groups even in…”
Get full text

Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology by Bagatell, Rochelle, Park, Julie R, Acharya, Sahaja, Aldrink, Jennifer, Allison, Jenna, Alva, Elizabeth, Arndt, Carola, Benedetti, Daniel, Brown, Erin, Cho, Steve, Church, Alanna, Davidoff, Andrew, Desai, Ami, DuBois, Steven, Fair, Douglas, Farinhas, Joaquim, Harrison, Douglas, Huang, Frederick, Iskander, Paul, Kreissman, Susan, Macy, Margaret, Na, Brian, Pashankar, Farzana, Pendyala, Praveen, Pinto, Navin, Polites, Stephanie, Rabah, Raja, Shimada, Hiroyuki, Slatnick, Leonora, Sokol, Elizabeth, Twist, Clare, Vo, Kieuhoa, Watt, Tanya, Wolden, Suzanne, Zage, Peter, Schonfeld, Ryan, Hang, Lisa

“…Neuroblastoma is the most common extracranial solid tumor diagnosed in children. This inaugural version of the NCCN Guidelines for Neuroblastoma provides…”
Get more information

Synthesis and Systematic Study on the Effect of Different PEG Units on Stability of PEGylated, Integrin-αvβ6-Specific A20FMDV2 Analogues in Rat Serum and Human Plasma by Hung, Kuo-Yuan, Kowalczyk, Renata, Desai, Ami, Brimble, Margaret A, Marshall, John F, Harris, Paul W R

“…A20FMDV2 is a 20-mer peptide that exhibits high selectivity and affinity for the tumour-related αvβ6 integrin that can compete with extracellular ligands for…”
Get full text

Veno-occlusive disease after high-dose busulfan–melphalan in neuroblastoma by Schechter, Tal, Perez-Albuerne, Evelio, Lin, Tiffany F., Irwin, Meredith S., Essa, Mohammed, Desai, Ami V., Frangoul, Haydar, Yanik, Gregory, Dupuis, L. Lee, Jacobsohn, David, Kletzel, Morris, Ranalli, Mark, Soni, Sandeep, Seif, Alix E., Grupp, Stephan, Dvorak, Christopher C.

“…Survival for high-risk neuroblastoma patients is still suboptimal. Although stem cell transplantation (SCT) is used, there is no consensus as to which…”
Get full text

Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531 by Barr, Erin K., Naranjo, Arlene, Twist, Clare J., Tenney, Sheena C., Schmidt, Mary Lou, London, Wendy B., Gastier‐Foster, Julie, Adkins, E. Stanton, Mattei, Peter, Handler, Michael H., Matthay, Katherine K., Park, Julie R., Maris, John M., Desai, Ami V., Cohn, Susan L.

“…Background We previously reported excellent three‐year overall survival (OS) for patients with newly diagnosed intermediate‐risk neuroblastoma treated with a…”
Get full text

Reply to K. Beiske et al by Sokol, Elizabeth, Desai, Ami V, Applebaum, Mark A, Valteau-Couanet, Dominique, Park, Julie R, Pearson, Andrew D J, Schleiermacher, Gudrun, Irwin, Meredith S, Hogarty, Michael, Naranjo, Arlene, Volchenboum, Samuel, Cohn, Susan L, London, Wendy B

Get full text

Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high‐risk neuroblastoma using a national administrative database by Desai, Ami V., Li, Yimei, Getz, Kelly, Seif, Alix E., Fisher, Brian, Huang, Vera, Aplenc, Richard, Bagatell, Rochelle

“…Background High‐dose chemotherapy with autologous stem cell rescue (HDC‐ASCR) has improved event‐free survival for children with high‐risk neuroblastoma…”
Get full text